Uptake of Novel Therapies Into First-Line Treatment for Acute Myeloid Leukemia Patients: EU4 + UK Perspective

References

• Freireich EJ, Wiernik PH, Steensma DP. The leukemias: a half-century of discovery. J. Clin. Oncol. 32(31), 3463–3469 (2014).
   PubMed Web of Science ®Google Scholar
• Genovese G, Kähler AK, Handsaker RE et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371(26), 2477–2487 (2014).
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 374(23), 2209–2221 (2016).
   PubMed Web of Science ®Google Scholar
• Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer. 2(2), 95–107 (2011).
   PubMedGoogle Scholar
• Small D. Targeting FLT3 for the treatment of leukemia. Semin. Hematol. 45(2 Suppl. 3), S17–S21 (2008).
   PubMed Web of Science ®Google Scholar
• Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat. Rev. Cancer. 4(5), 394–400 (2004).
   PubMed Web of Science ®Google Scholar
• Grisendi S, Mecucci C, Falini B et al. Nucleophosmin and cancer. Nat. Rev. Cancer. 6(7), 493–505 (2006).
   PubMed Web of Science ®Google Scholar
• Becker JS, Fathi AT. Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation. Curr. Cancer Drug Targets. 20(7), 490–500 (2020).
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4), 424–447 (2017).
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Bixby D, Perl A et al. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J. Natl Compr. Canc. Netw. 19(1), 16–27 (2021).
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Ravandi F, Liu-Dumlao T et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 20(24), 4840–4845 (2012).
   Google Scholar
• Othus M, Kantarjian H, Petersdorf S et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson. Leukemia. 28(2), 289–292 (2014).
   PubMed Web of Science ®Google Scholar
• Wei AH, Strickland SA Jr , Hou JZ et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. J. Clin. Oncol. 37(15), 1277–1284 (2019).
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1), 7–17 (2019).
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N. Engl. J. Med. 377(5), 454–464 (2017).
   PubMed Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood 135(7), 463–471 (2020).
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6), 722–731 (2017).
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, Phase III study. [published correction appears in Lancet. 2018 Feb 8]. Lancet 379(9825), 1508–1516 (2012).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 33(2), 379–389 (2019).
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J. Clin. Oncol. 36(26), 2684–2692 (2018).
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N. Engl. J. Med. 381(18), 1728–1740 (2019).
   PubMed Web of Science ®Google Scholar
• Wei A, Dohner H, Pocock C et al. The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission. Blood 134(Suppl. 2), LBA3 (2019).
   Google Scholar
• Eghtedar A, Borthakur G, Ravandi F et al. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am. J. Hematol. 87(3), 317–318 (2012).
   PubMed Web of Science ®Google Scholar
• Labrador J, Martínez-Cuadrón D, de la Fuente A et al. Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry. Blood 136(Suppl. 1), 25–27 (2020).
   Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N. Engl. J. Med. 383(7), 617–629 (2020).
   PubMed Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a Phase III randomized placebo-controlled trial. Blood 135(24), 2137–2145 (2020).
   PubMed Web of Science ®Google Scholar